Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Pierre Combe

ResearcherPublications, citations & collaboration network

Pierre Combe is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 101 works, 4,420 citations, an h-index of 18 and an i10-index of 26.

101
Works
4,420
Citations
18
h-index
26
i10-index

How has Pierre Combe's publication output changed over time?

ScholarIQpublication output · 2015–2023

Output grew0% over the shown period — from 1 works in 2015 to 1 in 2023.

1
4
1
1
1
1
1
2015201620172019202020212023

What are the most-cited papers on Pierre Combe?

ScholarIQmost cited works
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martı́n, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre‐Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Éric Pujade-Lauraine, Philipp Harter
New England Journal of Medicine. 20192,070 CitationsOPEN ACCESS
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron, Orianne Colussi, Elie Marcheteau, Simon Pernot, Mevyn Nizard, Anne‐Laure Pointet, Sabrina Latreche, Sonia Bergaya, Nadine Benhamouda, Corinne Tanchot, Christian Stockmann, Pierre Combe, Anne Berger, Franck Zinzindohoué, Hideo Yagita∥, Éric Tartour, Julien Taı̈eb, Magali Terme
S22947807. 20151,170 CitationsOPEN ACCESS
Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
Clémence Granier, Charles Dariane, Pierre Combe, Virginie Verkarre, Saı̈k Urien, Cécile Badoual, Hélène Roussel, Marion Mandavit, Patrice Ravel, Mathilde Sibony, Lucie Biard, C. Radulescu, Emeline Vinatier, Nadine Benhamouda, Michaël Peyromaure, Stéphane Oudard, Arnaud Méjean, Marc‐Olivier Timsit, Alain Gey, Éric Tartour
Cancer Research. 2016210 CitationsOPEN ACCESS
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Benoît You, Patrick Robelin, Michel Tod, Christophe Louvet, Jean‐Pierre Lotz, Sophie Abadie‐Lacourtoisie, Michel Fabbro, Christophe Desauw, Nathalie Bonichon-Lamichhane, Jean‐Emmanuel Kurtz, Philippe Follana, Marianne Leheurteur, Francesco Del Piano, Gwénaël Ferron, Gaëtan De Rauglaudre, Isabelle Ray‐Coquard, Pierre Combe, Annick Chevalier-Place, Florence Joly, Alexandra Léary, Éric Pujade-Lauraine, Gilles Freyer, Olivier Colomban
Clinical Cancer Research. 2020136 Citations
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin, Lisa Belin, Katharina Leitner, David Cibula, Hannelore Denys, Ora Rosengarten, Manuel Rodrigues, Nikolaus de Gregorio, Jerónimo Martínez, Edgar Petru, Roman Kocián, Ignace Vergote, Patricia Pautier, Barbara Schmalfeldt, Lydia Gaba, Stephan Polterauer, Marie‐Ange Mouret‐Reynier, Jalid Sehouli, Cristina Churruca, Frédèric Selle, Florence Joly, Véronique D’Hondt, Émilie Bultot-Boissier, Coriolan Lebreton, Jean‐Pierre Lotz, Rémy Largillier, Pierre‐Etienne Heudel, Florian Heitz, on behalf of the ATALANTE/ENGOT-ov29 Investigators, Jean‐Emmanuel Kurtz, Sophie Abadie‐Lacourtoisie, Cyril Abdeddaim, J. Alexandre, P. Augereau, D. Avenin, M. Azémar, Nabil Baba-Hamed, Olivia Bally, Jérôme Barrière, Fernando Bazán, Dominique Berton, Nathalie Bonichon-Lamichhane, Nathalie Bonnin, Elouen Boughalem, R. Boustany Grenier, Pierre-Emmanuel Brachet, Fabien Brocard, Émilie Bultot-Boissier, Maria Cappiello-Bataller, H. Castanie, L. Chaigneau, Camille Chakiba, Dorothée Chocteau-Bouju, Pierre Combe, Aurélie Comte, Elodie Coquan, Cristina Costan, P. Cottu, L. Crouzet, H. Curé, Jérôme Dauba, Hussain Dawood, Laure De Cock, T. De La Motte Rouge, C. Debelleix, Catherine Delbaldo, Martin Demarchi, Marion Deslandres, Raymond Despax, Véronique D’Hondt, Anne Françoise DILLIES-LEGRAIN, A Donnadieu, C. Dubot, Jean Marc Extra, Michel Fabbro, Claire Falandry, F. Fiteni, Anne Floquet, Philippe Follana, Jean‐Sébastien Frenel, G. Freyer, D. Garbay-Decoopman, Céline Gavoille, V. Girre, Laurence Gladieff, F. Goldwasser, Alain Gratet, Jean‐Christophe Grenier, Anne‐Claire Hardy‐Bessard, Pierre‐Etienne Heudel, Florence Joly, A. Jouinot, Emilie Kalbacher, Marie‐Christine Kaminsky, Laurence Lancry-Lecomte, R. Largillier, Fanny Le Du, Alexandra Léary
Journal of Clinical Oncology. 2023109 CitationsOPEN ACCESS

Related on ScholarIQ

Hôpital Européen
Institution
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Paper
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Paper
Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
Paper
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Paper
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Paper
470M+ articles · free account